Journal
CANCER COMMUNICATIONS
Volume 40, Issue 12, Pages 743-745Publisher
WILEY
DOI: 10.1002/cac2.12110
Keywords
Hepatocellular carcinoma; Atezolizumab; Bevacizumab; Sorafenib; Cost-effectiveness